Bladder cancer is the fifth most common cancer in Israel. Bladder EpiCheck is designed to identify the presence or absence of bladder cancer in the patients' urine samples.
The use of this test will allow a reduction in the number of invasive tests for patients under follow-up, by using the new test alternately with cystoscopy tests. In addition, the test may improve the early detection rates of the tumors, in particular flat tumors that are difficult to locate with an invasive test or imaging.